The Great Pharma Debate: Which Giant Will Dominate Your Portfolio?

A Pivotal Moment: HHS Advances Major Drug Pricing Rule for Review

Transatlantic Tremors: How US Drug Pricing Reforms Are Reshaping the Global Pharmaceutical Landscape

Trump's Bold Vision: Pushing for Direct Drug Deals to Slash Costs

Amneal Pharmaceuticals Eyes Major Market Entry with Xolair Biosimilar, Pledging Affordable Relief

Historic Shift: White House Reviews Landmark Drug Price Negotiation Rule

Market Movers: Unpacking the Week's Most Impactful Corporate Deals and Strategic Shifts

Roche's Strategic Investment Ignites Excitement in the MASH Drug Development Landscape

The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance

Metsera: The New Power Player Set to Disrupt the $100 Billion GLP-1 Market

Mpox in Africa: A Grave, Enduring Health Emergency Declared by WHO

Halozyme gains as U.S. and EU clear Enhanze based products